Karolinska Development – Q2 2016 Interim Report - invitation to conference call and webcast
August 29, 2016 05:43 ET
|
Karolinska Development AB
Please dial in at one of the following numbers a few minutes before the start of the conference call:
From Sweden: +46 (0) 8 505 564 74
From the US: +1 855 753 22...
Karolinska Development – Delårsrapport för januari - juni 2016, inbjudan till telefonkonferens och webbpresentation
August 29, 2016 05:43 ET
|
Karolinska Development AB
Vänligen ring in på något av följande telefonnummer några minuter före telefonkonferensens start:
Från Sverige: +46 (0) 8 505 564 74
Från USA: +1 855 753 22 30
Från Storbritannien: +44...
Umecrine Cognition appoints Dr. Bruce Scharschmidt to its board of directors
July 06, 2016 02:00 ET
|
Karolinska Development AB
Dr. Scharschmidt most recently served as Senior Vice President and Chief Medical & Development Officer at Hyperion Therapeutics (acquired by Horizon Pharma Inc. in 2015), where he was...
Karolinska Development divests its holding in Clanotech to Rosetta Capital
July 05, 2016 02:00 ET
|
Karolinska Development AB
KDev Investments, an investment fund jointly owned by Karolinska Development and Rosetta Capital, will transfer all its shares in Clanotech to Rosetta Capital. Karolinska Development retains an...
Karolinska Development avyttrar sitt innehav i Clanotech till Rosetta capital
July 05, 2016 02:00 ET
|
Karolinska Development AB
KDev Investments AB, ett investmentbolag gemensamt ägt av Karolinska Development och Rosetta Capital, överför hela sitt innehav i Clanotech till Rosetta Capital. Karolinska Development bibehåller...
Aprea AB Names Christian S. Schade President & Chief Executive Officer
June 16, 2016 02:00 ET
|
Karolinska Development AB
“I am delighted to welcome Chris to Aprea,” said Bernd R. Seizinger, M.D., Ph.D., Chairman of the Board of Directors. “He is an accomplished biopharmaceutical executive with proven experience...
Dilaforette poster presentation at EHA Congress
June 09, 2016 02:00 ET
|
Karolinska Development AB
Dilaforette’s submission is entitled: ‘Sevuparin Demonstrates Binding to Key Adhesion Receptors Involved in Pathogenesis of Sickle-Cell Disease’ under session for non-malignant hematopoetic...
Lipidor and Cadila Pharmaceuticals announce agreement on Phase III Clinical Study and joint commercialization of topical Psoriasis product
June 01, 2016 02:00 ET
|
Karolinska Development AB
“We are very pleased with our collaboration with Cadila Pharmaceuticals, which will enable us to bring this important psoriasis product to the market”, said Dr. Anders Carlsson, CEO of Lipidor...
Karolinska Development´s Annual General Meeting 2016
May 26, 2016 02:00 ET
|
Karolinska Development AB
Profit and loss statement and the balance sheet: It was resolved to adopt the profit and loss statement and the balance sheet and the consolidated profit and loss statement and the consolidated...
Karolinska Developments årsstämma 2016
May 26, 2016 02:00 ET
|
Karolinska Development AB
Redovisning: Beslöts att fastställa resultat- och balansräkningen samt koncernredovisningen och koncernbalansräkningen.
Resultatdisposition: Beslöts att godkänna styrelsens och verkställande...